RayKnowChina Research Map
Shortlist

RecruitingGliomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression

An open trial on glioma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07670026, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically confirmed Glioblastoma.

    Inclusion criterion 3

  3. Subtotal resection or recurrent/progressive disease 4-6 weeks after surgery (before radiotherapy).

    Inclusion criterion 4

    Negative serum pregnancy test, and effective contraceptive measures from signing the informed consent form until 6 months after the last chemotherapy.

    Inclusion criterion 11

    Currently participating in another clinical study, or less than 4 weeks since completion of treatment in a previous clinical study.

    Exclusion criterion 1

  4. Complete blood count: absolute neutrophil count (ANC) >=1.5*10\^9/L (1500/mm3), platelets >=75*10\^9/L, hemoglobin >=9 g/dL (if there is bone marrow involvement, platelets >=50*10\^9/L, ANC >=1.0*10\^9/L, hemoglobin >=8 g/dL).

    Inclusion criterion 6

    Liver function: serum bilirubin <=1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=1.5 times ULN (if there is liver involvement, AST and ALT <=5 times ULN are allowed).

    Inclusion criterion 7

    Renal function: serum creatinine <=1.5 times ULN.

    Inclusion criterion 8

    Coagulation function: INR <=1.5 times ULN; PT and APTT <=1.5 times ULN (unless the subject is receiving anticoagulant therapy and PT and APTT at screening are within the expected range for anticoagulant therapy).

    Inclusion criterion 9

  5. History of malignancy other than Glioblastoma within the past 3 years, or another uncured primary malignancy.

    Exclusion criterion 2

  6. Pregnant or lactating women.

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07670026, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntary participation in the clinical study: fully understands and is informed about the study and has signed the informed consent form in writing; willing to comply with and able to complete all trial procedures.
  • Age: >=18 years; male or female.
  • Pathologically confirmed Glioblastoma.
  • Subtotal resection or recurrent/progressive disease 4-6 weeks after surgery (before radiotherapy).
  • Adequate organ and bone marrow function, with no severe hematopoietic dysfunction or cardiac, pulmonary, hepatic, renal dysfunction, or immunodeficiency:
  • Complete blood count: absolute neutrophil count (ANC) >=1.5*10\^9/L (1500/mm3), platelets >=75*10\^9/L, hemoglobin >=9 g/dL (if there is bone marrow involvement, platelets >=50*10\^9/L, ANC >=1.0*10\^9/L, hemoglobin >=8 g/dL).
  • Liver function: serum bilirubin <=1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=1.5 times ULN (if there is liver involvement, AST and ALT <=5 times ULN are allowed).
  • Renal function: serum creatinine <=1.5 times ULN.
  • Coagulation function: INR <=1.5 times ULN; PT and APTT <=1.5 times ULN (unless the subject is receiving anticoagulant therapy and PT and APTT at screening are within the expected range for anticoagulant therapy).
  • Left ventricular ejection fraction (LVEF) >=50% on cardiac function examination.
  • Negative serum pregnancy test, and effective contraceptive measures from signing the informed consent form until 6 months after the last chemotherapy.
  • Thyroid-stimulating hormone (TSH), free thyroxine (FT4), or free triiodothyronine (FT3) within the normal range ±10%.
  • Ophthalmologic examination: including dilated fundus examination, slit-lamp examination, and color fundus photography.

Exclusion Criteria:

  • Currently participating in another clinical study, or less than 4 weeks since completion of treatment in a previous clinical study.
  • History of malignancy other than Glioblastoma within the past 3 years, or another uncured primary malignancy.
  • Prior history of brain radiotherapy.
  • Pregnant or lactating women.
  • Patients assessed as having contraindications to radiotherapy.
  • Severe active comorbidity that would affect the study treatment.
  • Active infection requiring systemic anti-infective treatment, including but not limited to bacterial, fungal, or viral infection.
  • Within 6 months before screening, New York Heart Association (NYHA) class III or IV heart failure, unstable angina, severe poorly controlled ventricular arrhythmia, or electrocardiographic evidence of acute ischemia or myocardial infarction.
  • QTcF interval >480 msec, unless secondary to bundle branch block.
  • Uncontrolled concomitant disease, including but not limited to uncontrolled hypertension, active peptic ulcer disease, or hemorrhagic disease.
  • Prior history of mental illness; lack of capacity for civil conduct or limited capacity for civil conduct.
  • Any medical history or disease evidence, treatment, or abnormal laboratory value that may interfere with trial results or prevent the subject from fully participating in the study, or any other condition that the investigator considers unsuitable for enrollment.

Quoted from ClinicalTrials.gov, NCT07670026, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07670026, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07670026